Search Results
ARROW study: pralsetinib in RET fusion+ tumors
ARROW: precision targeted therapy with pralsetinib for RET fusion+ tumors
ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors
ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen Liu
Pralsetinib in Chinese patients with advanced RET fusion+ NSCLC
ARROW points the way for RET fusion-positive NSCLC treatment | Stephen Liu
Pralsetinib for Advanced or Metastatic RET-Altered Thyroid Cancer with Dr. Vivek Subbiah
ARROW: an update on the registrational study
RET fusion-positive mNSCLC: selpercatinib and pralsetinib
ASCO 2021 - Blueprint Medicines - ARROW Study Updated Results
Selpercatinib and Pralsetinib in RET + Disease - Lung Cancer Video Library
Designing clinical trials for precision oncology
